抄録
Clinical studies were carried out to investigate the nature of potentiation of antimicrobial activity of sulfamethoxazole (SMX) by trimethoprim (TMP). The results are summarized as follows;
1. FIC indices of the SMX-TMP combination against Escherichia coli isolated from clinical materials ranged 0. 05 to 0. 083.
2. The antibacterial activity of urine collected from patients following administration of SMX-TMP combination product was potentiated by a few times than that of SMX alone, indicating therapeutic efficacy of this combination product in SMX-resistant infections.
3. Detail blood counts and tests of the liver and renal function in healthy volunteers revealed no detectable abnormalities after 7 day treatment of 0. 7 g TMP daily. Further evaluation along the similar line in anemic patients may be of value. No untoward effects on spermatogenesis were detected after 7 to 14 days of treatment with SMX-TMP combination product in an ordinary dosage.
4. The results of SMX-TMP combination product in infections of the female reproductive system confirmed its therapeutic efficacy. The efficacy of the combination of SMX-TMP was found to be clearly superior to that of SMX or TMP alone in a preliminary sequential trial.
